THERAPY DOSSIER · th-77b7512836a7

Human fetal neural stem cells NSI-566 (GFP-labelled)

Biologic

Evidence & regulatory context

Mechanism: Not recorded
Target: Not recorded
Injury models: TBI
Reported indication: Not recorded
First approval: Not recorded
Development stage: Not recorded
ChEMBL record: Not recorded
ChEMBL max phase: Not recorded
Synonyms: Not recorded
Note: Not recorded

Clinical trials 1

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

NCT03296618 ↗PHASE1unknown

Phase I Clinical Study of Intracerebral Transplantation of Neural Stem Cells for the Treatment of Ischemic Stroke (NSI-566)

Ischemic Motor Stroke, Chronic

Enrolment: 18 · Results not recorded

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 31626023 ↗2020Reported benefit

Human neural stem cell transplant location-dependent neuroprotection and motor deficit amelioration in rats with penetrating traumatic brain injury.

RatTBIPenetrating / ballisticSprague-DawleyMalen = n = 10 per group randomised across four groups; final footf…Stereotactic intracerebral transplantation into the lesion core or surrounding tissue1 million cells at 50,000 cells/uL; intralesional as a sing…1 week after injury, once motor deficit was established

Model: Unilateral penetrating ballistic-like traumatic brain injury: probe inserted 12 mm through a burr hole and inflated to 6.33 mm diameter for 40 milliseconds

Transplantation one week after penetrating traumatic brain injury attenuated motor deficits at both locations, but only perilesional transplantation reduced lesion volume (9.17 plus or minus 1.53% versus 22.53 plus or minus 2.87% for vehicle) and increased cortical and motor cortex sparing.

Extraction: extract · Subtype source: rule · Supplied extraction confidence: 0.8. Machine-extracted fields require source verification.

Loading the evidence…